We previously demonstrated that atherogenic Ldlr
INTRODUCTION
Atherosclerosis is characterized by the interplay between modified lipoprotein particles and the immune system in the vascular wall resulting in the initiation and progression of the disease development (1, 2) . Although aggressive lipid lowering therapeutics aimed to reduce low-density lipoprotein (LDL) cholesterol is currently the standard practice of care in both primary and secondary prevention of atherosclerotic cardiovascular disease (3) , addressing the underlying immune regulation of atherosclerosis development may offer an alternative therapeutic approach.
Various studies have demonstrated the essential role of both innate and adaptive immunity in the pathogenesis of atherosclerosis (4) . Immune cells, such as macrophages, activated T lymphocytes and dendritic cells (DCs) are either recruited, or locally activated, resulting in their proliferation in the atherosclerotic lesions. This in turn, induces an intense inflammatory response, contributing to the development of vascular atherosclerosis (4-6). We and others have shown that Th17 cells are present in atherosclerotic lesions in hyperlipidemic mice and humans (7) (8) (9) (10) . However, the effects of Th17 responses on atherogenesis remain debatable (8, 11, 12) .
Proprotein convertase subtilisin/kexin type 9 (PCSK9) interacts with the low-density lipoprotein receptor (LDLR). This induces the lysosomal degradation of LDLR and results in an increase in plasma LDL cholesterol levels (13, 14) . However, PCSK9 may also affect atherosclerosis development via other non-LDLR-dependent mechanisms. Our laboratory has demonstrated that PCSK9 interacts directly with cytoplasmic apolipoprotein B (apoB) and prevents its degradation via the autophagosome/lysosome pathway, resulting in increased levels of very low-density lipoprotein (VLDL) and LDL production, which contributes to atherosclerosis development irrespective of the LDLR (15, 16) . Moreover, the LDLs generated from the PCSK9 expressing Ldlr 
Pcsk9
−/− (LTp) triple knockout mice. These observations provide further evidence that PCSK9 modulates atherosclerosis development independent of LDLR.
Since we have demonstrated that our hyperlipidemic double knockout LDb mice have increased Th17 cells in the atherosclerotic lesions (7), we have decided to assess the role of PCSK9 in the Th17 response and atherogenesis. We deleted the Pcsk9 gene from LDb mice to generate a triple knockout LTp mouse model. We report here that LTp triple knockout mice have significantly reduced atherosclerosis, virtually undetectable IL-17 in the atherosclerotic lesions, significantly reduced circulating IL-17 levels and reduced differentiation of IL-17-producing cells when compared with LDb mice. Thus, this study suggests that PCSK9 may play a role in modulating the inflammatory response and the development of atherosclerosis.
MATERIALS AND METHODS

Animal studies
C57BL/6J mice were purchased from the Jackson Laboratory (Bar Harbor, ME). ) mice were generated in our laboratory as described (15, 16) . All mice were bred and maintained in a specific pathogen-free barrier facility in vivarium with a 12:12 h dark-light cycle, and maintained on a standard laboratory chow diet. All animal experiments were conducted in accordance with the guidelines of the Animal Protocol Review Committee of the University of Texas Health Science Center at Houston (IACUC approval No. AWC 18-0157).
Flow cytometry
Lymphoid cells were obtained from the thymus or spleen of wild-type (WT) (C57BL/6J), LDb or LTp mice at 5 months of age. For surface staining, we stained with PE or PerCpCy5.5 anti-CD4 (GK1.5), PerCp-Cy5.5 anti-CD8a (53-6.7), APC anti-CD44 (IM7), or Pacific Blue anti-γδTCR (UC7-13D5). For intracellular cytokine staining, isolated lymphoid cells were stimulated with PMA (100 ng/ml, Sigma-Aldrich, St. Louis, MO, USA) and ionomycin (1 μM, Sigma-Aldrich) in the presence of Brefeldin A and Monensin (eBioscience, San Diego, CA, USA) for 4 h, followed by surface staining. The cells were then resuspended in permeabilization buffer (eBioscience) for 30 min at 4°C, followed by staining with PEconjugated anti-IL-17A (TC11-18H10.1), and Alexa488-conjugated anti-IFN-γ (clone: XMG1.2). The stained cells were analyzed by FACSAria II flow cytometer (BD Biosciences, San Jose, CA, USA), and the data were analyzed using FlowJo software (TreeStar, Ashland, OR, USA).
ELISA
To measure the levels of IL-17A in the circulation, serum was collected from 5 months old of WT (C57BL/6J), LDb or LTp mice. Mouse IL-17A were measured from serum using mouse IL-17A ELISA kit according to the manufacturer's instruction (BioLegend, San Diego, CA, USA).
To measure the levels of IL-17A in CD4 +
CD44
+ T cells, FACS sorted 2×10 5 of CD4 + CD44 + T cells were re-stimulated with different concentration of anti-CD3 (2C11, 0 μg/ml, 0.5 μg/ml, and 5 μg/ml) for 3 days and then the supernatant was harvested. Mouse IL-17A were measured from the collected samples using a mouse IL-17A ELISA kit.
Quantitative real-time RT-PCR
+ T cells were stimulated with anti-CD3 (1 μg/ml) for 4 h then total RNA was extracted with TRIzol (Invitrogen, Carlsbad, CA, USA) and reverse transcribed using amfiRivert reverse transcriptase (GenDepot, Baker, TX, USA) according to the manufacturer's protocol. Gene expression was measured with iTaq-SYBR Green Supermix (Bio-Rad Laboratories, Hercules, CA, USA) and the ABI-PRISM 7900 detection system (Applied Biosystems, Foster City, CA, USA). Data were normalized to expression of the β-actin gene. The primer pairs used in quantitative RT-PCR are described in our previous study (7) .
Quantification of atherosclerotic lesions
Atherosclerotic lesions were quantified by 2 methods: en face and aortic root cross-section. We analyzed 10 male littermates per group (LDb and LTp) at 5-months of age for en face and 5 males per group for aortic root cross-section. The en face method measures atherosclerotic lesions throughout the whole aortic tree from the aortic root to the bifurcation of the iliac arteries. The aortic root cross section quantifies atherosclerotic lesions at the aortic root. Both methods were described in detail by others (17) (18) (19) (20) and have been used routinely in our laboratory (7, 15, 16, (21) (22) (23) (24) .
En face atherosclerotic lesions: Briefly, mouse aorta was dissected and cleaned to remove adventitial tissues. The aorta was then cut opened longitudinally, pinned and fixed overnight in 10% neutrally buffered formalin. The aorta was stained with freshly prepared filtered Oil Red O solution (1.56 mg/ml in methanol). The image of the whole aorta and atherosclerotic lesions was captured and scanned. We used SigmaScan Pro 4.0 imaging software (SPSS Inc., Chicago, IL, USA) to quantify the total area of the aorta and the area of atherosclerotic lesions. The results are presented as the ratio of lesions (mm 2 ) divided by the total surface area of the aorta (mm 2 ) expressed as a percentage.
Aortic root cross-section:
The base of the heart containing the aortic sinus in each mouse was embedded in optimal cutting temperature compound at −80°C. The aortic sinus or aortic root was sequentially sectioned using a cryostat. Once all three aortic valves appeared, serial sections were collected at 5 μm/section. We collected 2 sections/slide and 9-10 slides/aorta until intact valves were no longer seen. Usually, approximately 18 sections were collected. We fixed and stained every other slide with Oil Red O. Six sections per aortic root were used for atherosclerotic lesion measurements. The images were captured by a Zeiss D1M microscope at 100× to cover the whole aortic root section. We carefully drew along the lesion areas which were measured using AxioVision Rel 4.8 software (Zeiss USA, Peabody, MA, USA). The results are presented as area of atherosclerotic lesions (μm 2 ).
Immunohistochemical analysis on IL-17
Mouse aortic sinus tissue slides were fixed in 4% paraformaldehyde and were incubated with goat anti-IL-17 (sc-6077; Santa Cruz Biotechnology, Dallas, TX, USA) or isotype control. The slides were further incubated with Alexa594-conjugated anti-goat IgG (Invitrogen) and were mounted with mounting medium containing DAPI (vector). The slides were examined with a Zeiss Axio Observer.D1M fluorescence microscope with DAPI or Texas Red filters. The intensity was determined using NIH ImageJ software.
Statistical analysis
Comparison between two groups was performed using 2-tailed unpaired t-tests with Welch correction (GraphPad Prism Software, version7; Graphpad Software, San Diego, CA, USA). A 2-tailed p<0.05 was considered to be statistically significant. Comparison of three groups (C57BL/6J, LDb and LTp) was also analyzed by 1-way ANOVA.
RESULTS
Deletion of PCSK9 decreases atherosclerosis under hyperlipidemia condition
We have demonstrated that atherogenic LDb double knockout mice have elevated LDL cholesterol and develop atherosclerosis spontaneously (7, 15, 16, (21) (22) (23) (24) . These mice also have increased plasma levels of IL-17 with increased numbers of Th17 cells in lymphoid organs (7) . PCSK9 is a new gene recently been shown to regulate LDL cholesterol levels and modulate atherosclerosis development in humans and mice. PCSK9 was also shown to have immunological effects on activation and maturation of DCs and plaque T cells by oxidized low-density lipoprotein (oxLDL) (25) . Thus, we proposed that PCSK9 could modulate IL-17 producing T cell differentiation in atherosclerosis development.
To understand the role of PCSK9 in the development of atherosclerosis, we deleted Pcsk9 gene from LDb mice to generate the triple knockout LTp mice. We have reported that triple knockout LTp mice have significantly lower total plasma cholesterol and triglyceride levels and markedly reduced atherosclerosis in the aorta when compared with LDb mice (15) , which is confirmed in the current study. Using en face quantitation of the aortic lesions, the percentage of plaque to total aortic surface area was significantly lower in the LTp mice than in the LDb mice (LTp vs. LDb, 4.95%±0.47% vs. 13.52%±1.20%; p<0.0001) (Fig. 1A) . Moreover, the total plaque area in the aortic sinus was approximately 8-fold less in the LTp mice than in the LDb mice (p=0.0043; Fig. 1B ). Of note, although the plasma cholesterol and triglyceride levels in the LTp mice were lower than those in the LDb mice (plasma cholesterol of C57BL/6J, LTp, and LDb; 78±8.1 mg/dl, 460±40 mg/dl, 522±41 mg/dl, respectively, p<0.0001; plasma triglyceride of C57BL/6J, LTp, and LDb; 29±6.8 mg/dl, 113±25 mg/dl, 155±26 mg/dl, respectively, p<0.0001; see Fig. 1C ), their levels were still more than 5-fold higher than those in the C57BL/6J mice. Thus, despite the markedly elevated lipid levels in the LTp mice relative to those seen in the WT animals, LTp mice had markedly reduced atherosclerosis.
PCSK9 is associated with alterations in CD4 + T cell populations in the thymus and spleen
In view of our previous study demonstrating that increased IL-17 producing T cells were associated with atherosclerosis development in the LDb double knockout mice (7), we assessed the influence of deficiency of PCSK9 in T cell populations in the thymus and spleen. We first addressed frequencies of T cell population in the thymus. Using flow cytometry, we compared the frequencies of CD4 + CD8
− T cells in the thymus of C57BL/6J, LDb and LTp mice ( Fig. 2A and B) . LDb mice had significantly fewer CD4 + CD8
− cells, compared to WT C57BL/6J mice (LDb vs. C57BL/6J, 5.05%±0.51% vs. 7.68%±0.71%; p=0.0222). In contrast, LTp mice had increased levels of CD4 + CD8
− cells (LTp, 6.80%±0.57%) similar to those in the WT mice, but the increment was not significant, compared with LDb mice or C57BL/6J WT.
Next, we compared the T cell population in the spleen of C57BL/6J, LDb and LTp mice. Similar to those described above in the thymus, in the spleen LDb mice had significantly Notably, LTp mice showed normal splenic cellularity and recovered the levels of CD4 + cells to that of C57BL/6J mice. Together, LTp mice showed comparable levels of CD4 + T cells in both thymus and spleen to those in the WT animals, whereas LDb mice had fewer CD4 + T cells in either the thymus or the spleen.
Deficiency of PCSK9 reduces IL-17 levels in plasma and atherosclerotic lesions and decreases IL-17 producing cells
Next, we studied the effect of deficiency of PCSK9 on IL-17 producing cells. Plasma IL-17 levels were markedly reduced in the LTp mice to levels lower than in WT C57BL/6J mice (C57BL/6J, LTp, and LDb; 4.75±4.75 pg/ml, 1.07±1.07 pg/ml, and 54.3±15.5 pg/ml, respectively; Fig. 3A) . Importantly, LTp mice also had markedly reduced levels of IL-17 in the lesions in the aortic sinus when compared with LDb mice (Fig. 3B) . We, then, studied γδTCR + T cells, one of the major sources of IL-17 (26, 27) . Using flow cytometry, we evaluated the total number of γδTCR + T cells (Fig. 3C) and the percentage of γδTCR + T cells (Fig. 3D) 
Deficiency of PCSK9 in the atherogenic mice affects T cell differentiation
Next, we addressed whether the deficiency of PCSK9 in the atherogenic condition affects T cell differentiation. By flow cytometry, we analyzed the effector-memory CD4 + T cells (CD44   hi   CD4 + T cells) in the spleen (Fig. 4A) vs. 4.0%±1.8%; p values were not significant) (Fig. 4B) . We also quantified the effectormemory T cells' master transcription factor expression levels in CD44 hi CD4
+ sorted T cells from the spleen (Fig. 4C) . These cells have been stimulated with anti-CD3 at 1 µg/ml for 4 h. LDb mice had the highest relative levels of Rorc, Th17 cells master transcription factor, mRNA expression when compared to those in LTp or WT C57BL/6J mice (LDb, LTp, and C57BL/6J; 3.56±0.1.78, 1.58±0.71, and 0.83±0.18, respectively; p=0.0260 for LDb vs. LTp and p=0.01 for LDb vs. C57BL/6J; Fig. 4C) . The mRNA levels of Tbx21, Th1 cells master transcription factor, were similar among the WT C57BL/6J, LDb, and LTp mice (C57BL/6J, LDb, and LTp; 0.85±0.17, 0.82±0.15, and 0. 77±0.28, respectively; Fig. 4C) . Thus, the gene expression levels corroborated the T cell populations data.
To further evaluate the production of IL-17 from CD44 hi CD4
+ T cells in C57BL/6J, LDb, and LTp mice, we re-stimulated these CD44 hi CD4
+ T cells with plate-bound anti-CD3 Ab. Significantly more IL-17A was produced from LDb mice when compared to LTp or C57BL/6J WT mice. (LDb, LTp, and C57BL/6J; 8.9±6.8 ng/ml, 3.8±1.8 ng/ml, and 1.5±1.3 ng/ml at 0.5 µg/ml, respectively; LDb, LTp, and C57BL/6J; 18±15 ng/ml, 7.5±3.9 ng/ml, and2.3±2.6 ng/ml at 5 µg/ml, respectively; Fig. 4D ). Collectively, these results demonstrate that deletion of PCSK9 in LTp mice results in decreased the IL-17 in the circulation and reduced Th17 cell populations in the spleen. These results indicate that the deficiency of PCSK9 in the proatherogenic condition reverts the immune phenotypes to normal conditions when compared to WT mice.
DISCUSSION
In this study, we confirmed that atherogenesis could be modified by PCSK9 in the absence of LDLR. Even though LTp mice had lower lipid levels than LDb double knockout mice (the parental strain), LTp mice still have plasma lipid levels at 5-to 6-fold higher levels than the WT C57BL/6J animals. Yet, in the setting of dyslipidemia, LTp mice had virtually no plaque formation in the aortic sinus or the whole aorta, while LDb mice had extensive atherosclerosis. Since the atherogenic LDb mice had increased serum IL-17 levels and T cell programming shifted towards Th17 cells (7), we examined the effect of PCSK9 on IL-17 production in this study. We demonstrated that PCSK9 expression is associated with changes in T cell programming and IL-17 production. LTp mice were found to have reduced plasma and tissue levels of IL-17 when compared with LDb mice. The reduced IL-17 levels in LTp mice were associated with changes in major cellular sources of IL-17, namely Th17 cells and γδTCR + T cells. In the LTp mice, both the number and proportions of Th17 cells and γδTCR + T cells were decreased. In addition, Rorc expression level was decreased in the LTp mice. Furthermore, re-stimulated CD44 hi CD4 + T cells harvested from these animal models demonstrated different levels of IL-17 secretion, namely LTp mice had much lower levels of IL-17 secretion than the atherogenic LDb mice. In conclusion, the expression of PCSK9 is associated with changes in the polarization of IL-17-producing cells independent of its known effects on LDLR. This study represents the first study to demonstrate that PCSK9 can regulate atherogenesis and this is in part, mediated by changes in T cell programming and IL-17 production.
PCSK9 is best known for its effect on LDLR turnover, and its inhibition has resulted in dramatic reduction in plasma LDL cholesterol levels. In addition to its LDLR-dependent mechanisms, PCSK9 also has other LDLR-independent functions. Studies have shown that PCSK9 can directly interact with other receptors, such as the apoE receptor (28), LDLR-related protein 1 (29) , VLDL receptor (30), CD36 (31), CD81 (32) , and epithelial Na + channel (33) . We have shown that PCSK9 can directly control hepatic lipoprotein production via its interaction with cytoplasmic apoB which subsequently inhibits the degradation of apoB in the hepatocytes and results in increased secretion of proatherogenic VLDL and LDL (15) .
In this study, we specifically studied the association between PCSK9 and the adaptive immune response in T cells. We observed that the expression of PCSK9 had a profound effect on the expansion of IL-17-producing cells. A recent study also demonstrated that PCSK9 overexpression resulted in T cell-mediated inflammatory response in the lung and liver, disrupted T cell homeostasis and induced T cell expansion (34) . Increased γδTCR + T cells were found in hypercholesterolemic animals with atherosclerosis (35) and our study supports the mechanism that a reduction of γδTCR + T cells may attenuate atherogenesis. Studies using anti-PCSK9 Ab in BALB/c mice (36) or siRNA in human T cells (25) to inhibit PCSK9 show lower production of IFN-γ-and IL-17-producing cells. In comparison to C57BL/6J WT mice in our study, the CD44 hi CD4
+ T cells from LTp mice had increased IFN-γ-and IL-17-producing cells, but lower production of IL-17 cells than that of LDb mice. These suggest that hyperlipidemia play a role in activation of these effector cells. Th1 and Th17 lineages is complex and could be counter-regulate each other (37) , it is possible by inhibiting one target may cause an exacerbation of the other. Thus, this could explain that in CD44 Since dyslipidemia is present in both LDb and LTp mice, the question is whether PCSK9 alone could affect T cells differentiation. We have shown that PCSK9 alters VLDL and LDL metabolism in hepatocytes, producing proatherogenic LDLs which contain more cholesterol esters and phospholipids (15) . Human subjects treated with a PCSK9 inhibitor, produced lipoprotein particles with significant reduction in sphingolipids, cholesterol esters and free cholesterol levels (38) . Thus, the effects of PCSK9 on compositional changes in LDL may affect their likelihood of oxidation. Indeed, PCSK9 affects oxLDL-induced DC maturation (25) . oxLDL skews T cells differentiation to proatherogenic conditions (7) . Ceramide, has also been shown to alter T cell biology (39) . Collectively, changes in lipid composition in LDL in the setting of dyslipidemia may alter T cell response via cholesterol enrichment of T cell membranes that promotes Th1 differentiation of CD4 + T cells (40) or nanoclustering of T cell receptors in the cholesterol-enriched cell membrane that subsequently enhances the interactions between T cell receptors and Ag (41) . We hypothesized that PCSK9 influences LDL compositions in the liver to produce modified LDLs, and these modified LDLs, in turn, could act on T cells to alter T cell biology. It is also possible that the modified LDLs stimulated cytokine production from Ag presenting cells (APCs) such as DCs, macrophages, B cells, or non-professional APC, the different cytokines produced from the APCs could direct T cells into particular subtypes (42) . We present a schematic diagram (Fig. 5) to illustrate the potential mechanism of this study.
Given that plasma and tissue IL-17 levels were elevated in the LDb mice and suppressed in the LTp mice, we explored the cell types and signaling pathways responsible for such changes. In LDb mice, the expression of PCSK9 was associated with the expansion of IL-17-producing cells. The production of IL-17 was driven by the master transcription switch, Rorc. A previous study showed that hyperlipidemia promoted Rorc expression in the adipose tissues (43) , but it is yet to be determined if enhanced Rorc expression is related to other factors, such as TGF-β (44) . IL-17 is a pro-inflammatory cytokine that functions via mesenchymal and myeloid cells to induce secretion of diverse cytokines, chemokines, anti-microbial peptides and matrix metalloproteinases. IL-17 promotes endothelial cell activation via the p38MAPK pathway (45); increased expression of IL-17A receptor in apoE knockout mice reduces atherosclerotic lesions (46) . IL-17 also works synergistically with hypoxia and promotes migration and invasion of proinflammatory cells (47) . In addition, IL-17 is a pro-angiogenic factor (48) , which may promote neovascularization in complex atherosclerotic lesions. Despite these multiple mechanisms that might explain the pro-atherogenic properties of IL-17, the role of IL-17 in atherosclerosis remains controversial. Inhibition of IL-17A by anti-IL-17A Abs (49) , by the RORα/γ inverse agonist (50) and by IL-17A ablation (49) were effective in attenuating atherosclerotic lesion development in apoE mice. However, there is concern that the rat origin of the anti-IL-17A Abs may promote a Th2 response and may in part be responsible for the anti-atherogenic effects of the neutralizing Ab. In fact, studies using mouse-derived anti-mouse IL-17 Ab (51) and disruption of IL-17 expression in bone marrow-derived cells (52) did not alter atherosclerosis.
The presence of both LDLR and PCSK9 in apoE mice may confound the interpretation of the contribution of IL-17 in atherogenesis. This was taken into consideration in the current study by utilizing LTp mice with deletion of both LDLR and Pcsk9 genes. However, other studies suggested that IL-17 may stabilize plaque morphology via enhanced TGF-β signaling and collagen production by vascular smooth muscle cells (11, 53) . It is highly likely that the effects of IL-17 may be dependent on the inflammatory context. For instance, in the presence of anti-inflammatory combination of TGF-β1 and IL-6, there may be increased formation of IL-10-producing regulatory Th17 which may be protective against pathogenic Th1 cell differentiation (8) . Conversely, in the presence of pro-inflammatory IFN-γ, a concomitant increase in IL-17 may be pro-atherogenic (9). Finally, our study suggests that PCSK9 cross-links hyperlipidemia, atherosclerosis and immune responses mediated via IL-17-producing cells. Different subtypes of T cells yield different effects on atherogenesis. For example, studies in mice have provided that Th1 cells are atherogenic (25, 54) , while Th2 cells and Treg are atheroprotective (55) (56) (57) ; the role of Th17 is controversial (12, 58) , but our previous (7) and current studies provided evidence that Th17 is atherogenic. Moreover, recent studies demonstrate that T follicular helper (Tfh) cells promote atherosclerosis under a dyslipidemic condition (59) (60) (61) . What is the role of PCSK9 in all these different T cells subtypes? There is no evidence of direct role of PCSK9 on T cells; most studies examined PCSK9 in T cells are showing association effects of PCSK9 on activation of T cells by either through increasing cholesterol or oxLDL. Thus, all those studies support our hypothesis that PCSK9 influences the production of modified LDL, which affect T cell homeostasis.
It is evident from our study that PCSK9 attenuates the development of atherosclerosis and this phenomenon may not be dependent on the well-known interactions between PCSK9 and LDLR. We have also demonstrated that the pro-atherogenic effects of hyperlipidemia could be modified when PCSK9 is absent and this may be explained by altered T cell programming and IL-17 secretion by T cells in our LTp mouse model. Future studies will need to elucidate if the programming of other T cell subsets may also be altered in the setting of dyslipidemia and PCSK9 expression.
